Scan to Download ios&Android APP

Trade MyMD Pharmaceuticals, Inc. - MYMD CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 3.5099
52 wk Range N/A
Market Cap 176.21
P/E Ratio N/A
Shares Outstanding 38058200
Revenue N/A
EPS -0.8428
Dividend (Yield %) N/A
Beta 1.34467
Next Earnings Date Aug 15, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

MyMD Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, August 15, 2022
20:00
  US
Q2 2022 MyMD Pharmaceuticals Inc Earnings Release
Thursday, November 10, 2022
13:30
  US
Q3 2022 MyMD Pharmaceuticals Inc Earnings Release
Thursday, December 29, 2022
15:00
  US
MyMD Pharmaceuticals Inc Annual Shareholders Meeting
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 2.96091 3.35471 1.66557 0 0 0
Revenue 2.96091 3.35471 1.66557 0 0 0
Cost of Revenue, Total 1.08309 2.40613 1.53829 0 0 0
Gross Profit 1.87782 0.94858 0.12728 0 0 0
Total Operating Expense 6.28955 9.9685 12.5062 3.4721 12.2857 29.8948
Selling/General/Admin. Expenses, Total 3.84648 6.13088 7.44833 3.3971 4.32203 21.4561
Research & Development 1.18887 1.26038 1.06325 0 7.96368 6.7451
Depreciation / Amortization 0.17111 0.17111 0.17111 0
Unusual Expense (Income) 0 2.28524 0.075 0 1.08505
Operating Income -3.32864 -6.61379 -10.8406 -3.4721 -12.2857 -29.8948
Interest Income (Expense), Net Non-Operating 0.0251 0.01241 0.14394 0.10038 0.13653 0.00571
Net Income Before Taxes -3.30354 -7.36631 -10.849 -3.3813 -12.1522 -29.889
Net Income After Taxes -3.30354 -7.36631 -10.849 -3.3813 -12.1522 -29.889
Net Income Before Extra. Items -3.30354 -7.36631 -10.849 -3.3813 -12.1522 -29.889
Net Income -3.30354 -7.36631 -10.849 -3.88825 -17.5806 -29.889
Income Available to Common Excl. Extra. Items -3.30354 -7.36631 -10.849 -3.3813 -12.1522 -29.889
Income Available to Common Incl. Extra. Items -3.30354 -7.36631 -10.849 -3.88825 -17.5806 -29.889
Diluted Net Income -3.30354 -7.36631 -10.849 -3.88825 -17.5806 -29.889
Diluted Weighted Average Shares 0.01414 0.02473 0.22864 0.30634 3.52634 35.0172
Diluted EPS Excluding Extraordinary Items -233.593 -297.888 -47.4503 -11.0379 -3.44612 -0.85355
Diluted Normalized EPS -233.593 -297.888 -36.771 -10.7618 -3.44526 -0.82257
Other, Net -0.76493 0.00417
Gain (Loss) on Sale of Assets -0.15649 -0.00958 -0.00304
Total Extraordinary Items -0.50695 -5.4284
Other Operating Expenses, Total 0.60846
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Cost of Revenue, Total 0 0 0 0 0
Gross Profit 0 0 0 0 0
Total Operating Expense 3.0897 18.098 5.46629 3.24079 4.11741
Selling/General/Admin. Expenses, Total 1.07816 16.7478 1.64054 1.81824 1.49211
Research & Development 1.35098 1.48989 2.76766 1.30796 2.62974
Interest Expense (Income) - Net Operating 0.66056 0.04053 0 -0.70109 0
Unusual Expense (Income) 0 -0.18026 1.05809 0.20722 -0.00444
Operating Income -3.0897 -18.098 -5.46629 -3.24079 -4.11741
Interest Income (Expense), Net Non-Operating 0 0.00564 -0.00099 0.00106 -0.00462
Net Income Before Taxes -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Net Income After Taxes -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Net Income Before Extra. Items -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Net Income -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Income Available to Common Excl. Extra. Items -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Income Available to Common Incl. Extra. Items -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Diluted Net Income -3.0897 -18.0923 -5.46728 -3.23972 -4.12203
Diluted Weighted Average Shares 28.5533 35.9069 37.6348 37.8742 38.1229
Diluted EPS Excluding Extraordinary Items -0.10821 -0.50387 -0.14527 -0.08554 -0.10812
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10821 -0.50889 -0.11716 -0.08007 -0.10824
Other Operating Expenses, Total 0.60846
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 3.18694 7.7759 6.67013 10.3108 36.8428 12.6654
Cash and Short Term Investments 0.1227 5.45004 5.45475 9.68172 35.3364 11.559
Cash & Equivalents 0.0727 0.43843 0.18176 0.55597
Short Term Investments 0.05 5.01161 5.273 9.16427 16.7185 11.0031
Total Receivables, Net 0.65695 0.98126 0.18567 0.04288 1.20001
Accounts Receivable - Trade, Net 0.63316 0.96467 0.17633 0.04288
Total Inventory 2.03652 0.94761 0.58527 0.19899
Prepaid Expenses 0.37078 0.39699 0.44444 0.38723 0.29434 1.10635
Total Assets 5.08511 9.33789 7.80725 10.8849 36.8428 24.8129
Property/Plant/Equipment, Total - Net 0.25939 0.23511 0.08346 0.03357 0.14901
Property/Plant/Equipment, Total - Gross 2.40856 2.13687
Accumulated Depreciation, Total -2.14917 -2.1033
Intangibles, Net 1.30178 1.13067 0.24341 0.17042
Other Long Term Assets, Total 0.337 0.19621 0.81026 0.37012 0
Total Current Liabilities 1.69743 1.78504 1.9735 1.52977 2.2633 1.03987
Accounts Payable 1.46336 1.74522 1.9735 0.65729 2.2039 0.86752
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.23407 0.03982 0.05939 0
Total Liabilities 1.69743 1.78504 1.9735 1.52977 2.2633 1.16576
Total Long Term Debt 0 0 0 0 0 0
Total Equity 3.38768 7.55285 5.83375 9.35517 34.5795 23.6472
Redeemable Preferred Stock 0 1.755 0 0 0.14452 0.14452
Common Stock 100.892 110.647 121.555 128.92 171.599 102.064
Retained Earnings (Accumulated Deficit) -97.4795 -104.846 -115.695 -119.583 -137.164 -78.5616
Other Equity, Total -0.02457 -0.00347 -0.02591 0.01789 0
Total Liabilities & Shareholders’ Equity 5.08511 9.33789 7.80725 10.8849 36.8428 24.8129
Total Common Shares Outstanding 0.0142 0.11517 0.26006 0.86942 8.79263 37.6731
Total Preferred Shares Outstanding 0.00176 0 0 0.07299 0.07299
Cash 0.51744 18.618
Accrued Expenses 0.87247 0.17235
Other Current Assets, Total 0.012
Goodwill, Net 10.4985
Long Term Investments 1.5
Current Port. of LT Debt/Capital Leases 0
Long Term Debt 0
Other Liabilities, Total 0.12589
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 34.2979 22.3749 15.9476 12.6654 10.0722
Cash and Short Term Investments 31.0499 21.6304 15.3778 11.559 9.18811
Cash 0.56937
Short Term Investments 30.4805 19.503 14.0028 11.0031 7.99889
Total Receivables, Net 3.02614
Prepaid Expenses 0.21411 0.74456 0.56983 1.10635 0.88412
Other Current Assets, Total 0.0077
Total Assets 35.7979 34.4483 28.0104 24.8129 22.2035
Other Long Term Assets, Total 1.5
Total Current Liabilities 2.37406 3.34816 2.09247 1.03987 2.46678
Accounts Payable 2.33575 3.29864 2.05354 0.86752 1.9961
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.03831 0
Total Liabilities 2.37406 3.37401 2.11845 1.16576 2.58138
Total Long Term Debt 0 0 0 0 0
Total Equity 33.4238 31.0743 25.8919 23.6472 19.6221
Redeemable Preferred Stock 0.14452 0.14452 0.14452 0.14452 0.14452
Common Stock 171.926 100.784 101.069 102.064 102.161
Retained Earnings (Accumulated Deficit) -138.646 -69.8546 -75.3219 -78.5616 -82.6836
Total Liabilities & Shareholders’ Equity 35.7979 34.4483 28.0104 24.8129 22.2035
Total Common Shares Outstanding 8.32673 37.3557 37.4198 37.6731 38.0583
Total Preferred Shares Outstanding 0.07299 0.07299 0.07299 0.07299 0.07299
Cash & Equivalents 2.12737 1.37501 0.55597 1.18922
Property/Plant/Equipment, Total - Net 0.07487 0.06423 0.14901 0.13275
Goodwill, Net 10.4985 10.4985 10.4985 10.4985
Long Term Investments 1.5 1.5 1.5 1.5
Accrued Expenses 0.04952 0.03893 0.17235 0.47069
Other Liabilities, Total 0.02585 0.02598 0.12589 0.1146
Current Port. of LT Debt/Capital Leases 0 0
Long Term Debt 0 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -3.30354 -7.36631 -10.849 -3.88825 -12.1522 -29.889
Cash From Operating Activities -4.17315 -5.08041 -8.50219 -3.07428 -11.9249 -19.5165
Cash From Operating Activities 0.28616 0.24989 0.23449 0.07406 0.02945
Non-Cash Items -1.02503 2.72775 1.42741 0.91945 -0.62432 15.5544
Changes in Working Capital -0.13074 -0.69175 0.68495 -0.17955 0.82214 -5.18186
Cash From Investing Activities 3.84379 -5.0147 -0.35969 -3.94063 -8.75747 19.8506
Capital Expenditures -0.1233 -0.05451 -0.06821 0
Other Investing Cash Flow Items, Total 3.96709 -4.96019 -0.29147 -3.94063 -8.75747 19.8506
Net Change in Cash -0.32936 0.36573 0.24332 -0.04922 17.9854 0.40768
Cash From Financing Activities 10.4608 9.1052 6.96569 38.6678 0.07353
Issuance (Retirement) of Stock, Net 10.4608 9.1052 6.96569 38.6678 1.18984
Cash Taxes Paid 0.00207 0 0 0
Cash Interest Paid 0 0 0 0.2718
Amortization 0
Issuance (Retirement) of Debt, Net -1.11631
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -3.0897 -21.182 -26.6493 -29.889 -4.12203
Cash From Operating Activities -1.50518 -8.2585 -14.704 -19.5165 -2.36618
Non-Cash Items 0.66056 15.4688 15.5607 15.5544 0.10174
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0.2718 0.2718 0.2718 0
Changes in Working Capital 0.92396 -2.54521 -3.61539 -5.18186 1.65411
Cash From Investing Activities 0 11.3539 16.8522 19.8506 2.99944
Other Investing Cash Flow Items, Total 0 11.3539 16.8522 19.8506 2.99944
Cash From Financing Activities 1.79418 -1.11631 -0.92144 0.07353 0
Issuance (Retirement) of Debt, Net 1.79418 -1.11631 -1.11631 -1.11631 0
Net Change in Cash 0.289 1.97909 1.22673 0.40768 0.63326
Amortization 0 0 0
Issuance (Retirement) of Stock, Net 0.19487 1.18984

Still looking for a broker you can trust?

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

MyMD Pharmaceuticals, Inc. Company profile

About MyMD Pharmaceuticals Inc

MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Financial summary

BRIEF: For the nine months ended 30 September 2021, MyMD Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased from $9M to $26.6M. Higher net loss reflects Administrative Expenses - Balancing increase of 52% to $3.3M (expense), Personnel Costs - Administrative Expense increase of 61% to $1.3M (expense), Interest and Dividend Income decrease of 93% to $7K (income).

Industry: Biotechnology & Medical Research (NEC)

855 N. Wolfe Street
Suite 623
BALTIMORE
MARYLAND 21205
US

Income statement

People Also Watch

Ripple to US Dollar

0.37 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 0.00600

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading